• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受重组人酸性α-葡萄糖苷酶酶替代疗法治疗庞贝病的婴儿的动态心电图分析

Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.

作者信息

Cook Amanda L, Kishnani Priya S, Carboni Michael P, Kanter Ronald J, Chen Y T, Ansong Annette K, Kravitz Richard M, Rice Henry, Li Jennifer S

机构信息

Division of Pediatric Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

Genet Med. 2006 May;8(5):313-7. doi: 10.1097/01.gim.0000217786.79173.a8.

DOI:10.1097/01.gim.0000217786.79173.a8
PMID:16702882
Abstract

PURPOSE

Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase. Trials with recombinant human acid alpha-glucosidase enzyme replacement therapy (ERT) show a decrease in left ventricular mass and improved function. We evaluated 24-hour ambulatory electrocardiograms (ECGs) at baseline and during ERT in patients with infantile Pompe disease.

METHODS

Thirty-two ambulatory ECGs were evaluated for 12 patients with infantile Pompe disease from 2003 to 2005. Patients had a median age of 7.4 months (2.9-37.8 months) at initiation of ERT. Ambulatory ECGs were obtained at determined intervals and analyzed.

RESULTS

Significant ectopy was present in 2 of 12 patients. Patient 1 had 211 and 229 premature ventricular contractions (0.2% of heart beats) at baseline and at 11.5 weeks of ERT, respectively. Patient 2 had 10,445 premature ventricular contractions (6.7% of heart beats) at 11 weeks of therapy.

CONCLUSION

Infantile Pompe disease may have preexisting ectopy; it may also develop during the course of ERT. Therefore, routinely monitoring patients using 24-hour ambulatory ECGs is useful. Periods of highest risk may be early in the course of ERT when there is a substantial decrease in left ventricular mass and an initial decrease in ejection fraction.

摘要

目的

婴儿型庞贝病由溶酶体酸性α-葡萄糖苷酶缺乏引起。重组人酸性α-葡萄糖苷酶酶替代疗法(ERT)试验显示左心室质量减轻且功能改善。我们评估了婴儿型庞贝病患者在基线期和ERT期间的24小时动态心电图(ECG)。

方法

对2003年至2005年12例婴儿型庞贝病患者的32份动态心电图进行了评估。患者开始ERT时的中位年龄为7.4个月(2.9 - 37.8个月)。按确定的间隔获取动态心电图并进行分析。

结果

12例患者中有2例存在明显的心律失常。患者1在基线期和ERT治疗11.5周时分别有211次和229次室性早搏(占心跳的0.2%)。患者2在治疗11周时有10445次室性早搏(占心跳的6.7%)。

结论

婴儿型庞贝病可能预先存在心律失常,也可能在ERT过程中发生。因此,使用24小时动态心电图对患者进行常规监测是有用的。风险最高的时期可能是在ERT过程早期,此时左心室质量大幅下降且射血分数初步降低。

相似文献

1
Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.接受重组人酸性α-葡萄糖苷酶酶替代疗法治疗庞贝病的婴儿的动态心电图分析
Genet Med. 2006 May;8(5):313-7. doi: 10.1097/01.gim.0000217786.79173.a8.
2
Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.庞贝病婴儿接受酸性α-葡萄糖苷酶替代治疗后的心脏重塑。
Pediatr Cardiol. 2008 Nov;29(6):1033-42. doi: 10.1007/s00246-008-9267-3. Epub 2008 Jul 26.
3
Electrocardiographic response to enzyme replacement therapy for Pompe disease.庞贝病酶替代疗法的心电图反应。
Genet Med. 2006 May;8(5):297-301. doi: 10.1097/01.gim.0000195896.04069.5f.
4
Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.应用心脏磁共振成像评估接受酶替代治疗的婴儿型庞贝病患儿的心脏结构、功能和纤维化。
Mol Genet Metab. 2010 Dec;101(4):332-7. doi: 10.1016/j.ymgme.2010.07.011. Epub 2010 Jul 23.
5
Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease.接受婴儿型庞贝病酶替代疗法患者的心律失常
Genet Med. 2008 Oct;10(10):758-62. doi: 10.1097/GIM.0b013e318183722f.
6
Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.酶替代疗法和免疫疗法使两名庞贝病患儿的功能得到显著改善:病例报告
J Med Case Rep. 2024 Jul 18;18(1):328. doi: 10.1186/s13256-024-04638-5.
7
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.使用源自牛奶的重组人α-葡萄糖苷酶对庞贝氏病进行长期静脉治疗。
Pediatrics. 2004 May;113(5):e448-57. doi: 10.1542/peds.113.5.e448.
8
Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.经典婴儿型庞贝病治疗 13 年后的心脏结局:重组人酸性α-葡萄糖苷酶治疗。
Int J Cardiol. 2018 Oct 15;269:104-110. doi: 10.1016/j.ijcard.2018.07.091. Epub 2018 Jul 19.
9
Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.经典型婴儿庞贝病的酶替代疗法:一项为期十个月的随访研究结果
Neuropediatrics. 2005 Feb;36(1):6-11. doi: 10.1055/s-2005-837543.
10
A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.β受体阻滞剂普萘洛尔会降低庞贝病酶替代疗法的疗效。
Mol Genet Metab. 2016 Feb;117(2):114-9. doi: 10.1016/j.ymgme.2015.09.012. Epub 2015 Oct 3.

引用本文的文献

1
Enzyme replacement therapy for infantile-onset Pompe disease.婴儿型庞贝病的酶替代疗法。
Cochrane Database Syst Rev. 2017 Nov 20;11(11):CD011539. doi: 10.1002/14651858.CD011539.pub2.
2
Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy.迟发性庞贝病的心血管异常和酶替代治疗反应。
Genet Med. 2011 Jul;13(7):625-31. doi: 10.1097/GIM.0b013e3182142966.
3
A review of treatment of Pompe disease in infants.婴儿庞贝病治疗综述。
Biologics. 2007 Sep;1(3):195-201.
4
Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease.接受婴儿型庞贝病酶替代疗法患者的心律失常
Genet Med. 2008 Oct;10(10):758-62. doi: 10.1097/GIM.0b013e318183722f.
5
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.6neo/6neo型庞贝病小鼠的颞叶神经病理学和行为表型
J Neuropathol Exp Neurol. 2008 Aug;67(8):803-18. doi: 10.1097/NEN.0b013e3181815994.
6
Acid alpha-glucosidase deficiency (Pompe disease).酸性α-葡萄糖苷酶缺乏症(庞贝病)。
Curr Neurol Neurosci Rep. 2007 Jan;7(1):71-7. doi: 10.1007/s11910-007-0024-4.
7
Pompe disease diagnosis and management guideline.庞贝病诊断与管理指南。
Genet Med. 2006 May;8(5):267-88. doi: 10.1097/01.gim.0000218152.87434.f3.